Strategic Acquisition ProtaTek International was acquired by Pharmgate LLC in 2016, indicating potential opportunities for collaboration or service expansion with pharmaceutical and biotech entities involved in vaccine development and animal health.

Specialized Niche Operating within the biotechnology research sector with a focus on vaccine development for swine, ProtaTek presents a niche market opportunity to partners targeting veterinary health and agricultural biotech solutions.

Growth Potential With revenue estimates between 1M and 10M and a small team of 2-10 employees, there is potential for scale-up and new funding avenues, especially through partnership with larger biotech firms or investors seeking to expand vaccine research.

Technology Stack Utilizing advanced technologies such as Microsoft Azure, Windows Server, and cloud-based tools, ProtaTek demonstrates openness to innovative solutions that can be leveraged for enhanced research, manufacturing, or digital engagement strategies.

Market Positioning Although a small player, ProtaTek's focus on vaccine development aligns with broader industry growth in animal health and biotech, offering opportunities for suppliers of biotech infrastructure, lab equipment, and related services targeting small biotech firms.